Now, with the possibility of an effective vaccine hitting the market becoming a real possibility in the near future, many people have expressed doubts about the safety and efficacy of a vaccine that is developed in such a short time.
"If we add vaccines and forget the other things, Covid does not go to zero".
Pfizer and BioNTech announced that their COVID-19 vaccine has proven to be more than 95% effective on Wednesday.
Prof Trudie Lang, of the Nuffield Department of Medicine at the University of Oxford, said: "The detail on achieving 94% protection in the elderly participants in the trial is particularly excellent news".
Elliott said both Pfizer and Moderna's vaccines need to be stored at cold temperatures. Earlier this week, the company reported that it has already collected two months' worth of follow-up data about participants in its trial, which is a required component for said approval, and it's pursuing it with hopes of seeking that EUA "within days".
Moderna said its vaccine has side effects like muscle aches and fatigue. The shot helped to prevent severe disease, according to the analysis, with nine of 10 severe cases in the trial occurring in the placebo group.
But there are still some unanswered questions, including how long the immunity lasts.
Volunteers in the Phase 2 trial were divided into three groups.
More vaccine good news is what we've all been waiting for.
Republicans withdraw four lawsuits against election results
Another law firm on the case, Porter Wright Morris & Arthur LLP, gave notice last week that it's withdrawing from the case. After the 2016 recount voted totals increased by 713 for Democrat Hillary Clinton and 844 for Republican Donald Trump.
That process could still take a few weeks.
The statement said that the companies expect to produce up to 50 million vaccine doses this year on a global level, adding that they would produce another 1.3 billion doses by the end of 2021. But remember: it's a two-shot vaccine. That's good news for a country such as the United Kingdom, but not such good news for developing countries which haven't got the money to place bids.
Both are expected to be discussed by the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which is a panel of outside experts.
Pfizer and BioNTech had been working to accumulate two months of follow-up safety data on volunteers who had received the full two-dose regimen of their vaccine.
Pfizer, which did not accept research funding from the federal Operation Warp Speed initiative, has agreed to supply 100 million doses to the US government in exchange for $1.9 billion.
According to Nicole Hassoun, professor of philosophy at Binghamton University, State University of NY, buying, storing, shipping and administering these vaccines to the world population will be a hard and expensive endeavor, especially for third-world nations.
The US has said it expects it to be available to the general population by April.